Heme Degradation (Bilirubin Pathway)
- Compartment
- Reticuloendothelial system, liver ER, gut
- Main tissue
- Spleen/macrophages, liver, intestine
- Rate-limiting
- Heme oxygenase (HO-1 inducible; HO-2 constitutive); Bilirubin UDP-glucuronosyltransferase (UGT1A1)
- Steps
- 6
Reaction steps
In source order, 6 total
-
1
Heme + O₂ + NADPH + H⁺ → biliverdin IXα + Fe²⁺/³⁺ + CO + NADP⁺ + H₂O
Heme oxygenase (HO-1 inducible; HO-2 constitutive) 1.14.14.18 ST-0185 Irreversible rate-limiting NADP+ NADPH Fe2+ Heme/cytochrome O2 H2O› Notes
Heme oxygenase (HO-1 inducible; HO-2 constitutive) cleaves the α-methene bridge of heme in macrophage endoplasmic reticulum. It requires molecular oxygen, NADPH, and electrons delivered by NADPH–cytochrome P450 reductase; this is the rate-limiting, committed, and irreversible step of heme catabolism, and it liberates iron for recycling plus carbon monoxide.
-
2
Biliverdin IXα + NADPH + H⁺ → bilirubin IXα + NADP⁺
› Notes
Cytosolic biliverdin reductase reduces the central methine bridge to form unconjugated bilirubin. NADPH is required; bilirubin is hydrophobic and is released into plasma bound tightly but noncovalently to albumin.
-
3
Unconjugated bilirubin (albumin-bound) → hepatocyte-associated unconjugated bilirubin
OATP1B1/OATP1B3 uptake + ligandin binding (transport, not enzymatic) ST-0187 Irreversible/directional› Notes
Hepatic sinusoidal uptake is carrier-mediated (not a covalent enzymatic conversion), followed by cytosolic binding to ligandin/GST proteins. Albumin-bound bilirubin cannot be filtered by the kidney and is not directly excreted in urine.
-
4
Bilirubin + 2 UDP-glucuronic acid → bilirubin mono- and predominantly diglucuronide + 2 UDP
Bilirubin UDP-glucuronosyltransferase (UGT1A1) 2.4.1.17 ST-0188 Irreversible/directional rate-limiting UDP-glucuronic acid› Notes
Endoplasmic-reticulum bilirubin UDP-glucuronosyltransferase (UGT1A1) conjugates the two propionic-acid side chains using UDP-glucuronic acid. This is the rate-limiting enzymatic step of hepatic bilirubin clearance and produces water-soluble conjugated bilirubin; bilirubin diglucuronide is then actively secreted into bile by the ATP-dependent canalicular transporter MRP2 (ABCC2).
-
5
Conjugated bilirubin → unconjugated bilirubin → urobilinogen
↪ unconjugated bilirubin → urobilinogen
› Notes
Intestinal bacterial β-glucuronidases deconjugate bilirubin glucuronides, and bacterial reductases convert bilirubin to colorless urobilinogen. These are microbial rather than human enzymatic steps; no host ATP is directly consumed.
-
6
Urobilinogen → stercobilin (feces) or urobilin (urine)
› Notes
Most urobilinogen is oxidized in the intestine to brown stercobilin and excreted in feces; a portion is reabsorbed through portal blood, and a small fraction escapes hepatic uptake and is oxidized to yellow urobilin in urine. Enterohepatic cycling returns much of the absorbed urobilinogen to bile.
Showing all 6 steps.
Regulation
What speeds each enzyme up and what slows it down
Heme oxygenase-1 (HO-1)
Heme excess, oxidative stress, hypoxia, inflammatory stimuli
Reduced heme substrate availability; pharmacologic metalloporphyrins can inhibit
Stress/inflammatory transcriptional regulation predominates; no central acute endocrine switch
Biliverdin reductase
Biliverdin and NADPH availability
NADPH deficiency/product accumulation
No major direct hormonal control
UGT1A1
Bilirubin availability; maturation/induction of hepatic expression
UGT1A1 variants; some drugs that inhibit or compete for glucuronidation
Developmental regulation is major; neonatal activity is low. Hormonal effects are indirect through hepatic maturation and cholestatic states
MRP2 (canalicular export)
ATP and normal canalicular transport capacity
Cholestasis; MRP2 deficiency; ATP depletion
Bile-acid and nuclear-receptor signaling influence expression indirectly
Overview
Heme degradation disposes of heme released predominantly during turnover of senescent erythrocytes and converts its tetrapyrrole ring into bilirubin for biliary excretion. Macrophages first form biliverdin and unconjugated bilirubin; the water-insoluble bilirubin travels bound to albumin to liver, where it is conjugated with glucuronic acid and secreted into bile. Intestinal bacterial metabolism converts bilirubin-derived pigments to urobilinogen and ultimately to fecal stercobilin and urinary urobilin.
Cellular location
Initial heme breakdown is most active in reticuloendothelial macrophages of spleen, liver (Kupffer cells), and bone marrow, with heme oxygenase localized to the endoplasmic reticulum. Hepatic uptake, cytosolic ligand binding, and conjugation occur in hepatocytes; UDP-glucuronosyltransferase 1A1 (UGT1A1) is an endoplasmic-reticulum enzyme. Biliary secretion occurs across the canalicular membrane, while subsequent reduction/deconjugation occurs in the intestinal lumen through the microbiota.
Net energetics
Per heme molecule, heme oxygenase consumes 1 NADPH and O₂, and biliverdin reductase consumes 1 additional NADPH. Formation of bilirubin diglucuronide uses 2 UDP-glucuronic acid; their synthesis from glucose/UDP-glucose carries an upstream UTP-equivalent cost, while canalicular export by MRP2 is ATP dependent. No ATP is made by the pathway; recovered iron is reutilized for heme synthesis or stored as ferritin/hemosiderin.
Clinical significance
Bilirubin handling is clinically central because elevated unconjugated and conjugated bilirubin have distinct diagnostic implications. Unconjugated hyperbilirubinemia occurs with hemolysis, impaired uptake, or reduced conjugation (physiologic neonatal jaundice, Gilbert syndrome, Crigler–Najjar syndrome); because unconjugated bilirubin is lipid-soluble, severe neonatal elevation can cross the blood–brain barrier and cause kernicterus. Conjugated hyperbilirubinemia occurs with impaired canalicular excretion or biliary obstruction and can cause dark urine, whereas complete obstruction diminishes intestinal stercobilin and produces pale stools. Nucleotide metabolism supplies the purine and pyrimidine building blocks required for DNA replication, RNA synthesis, and energy carriers such as ATP and GTP, through both de novo synthesis and salvage of preformed bases. Because proliferating and immune cells have especially high nucleotide demand, these pathways are prominent targets of chemotherapeutic and immunosuppressive drugs. Inherited defects in nucleotide handling produce disorders ranging from gout to severe combined immunodeficiency.
Recent literature
Live Europe PMC search
Europe PMC · fetched just now · sorted by publication date
-
1
A transferrin receptor-targeted liposome for iron metabolism regulation-augmented photodynamic therapy in glioblastoma.
Wen R, He G, Wan Y, Guo X, Xiong S, Wu Y, Wei Y, Li D, Lin J, Huang P. · 2026-09-16
open access unreviewed -
2
Harnessing gasotransmitters for orthopaedic infection therapy: Mechanisms and advanced delivery platforms.
Zhang JY, Yang YQ, Zhang ZX, Jin JL, Luo ZY, Wang DY, Ruan CX, Dai TZ, Huang YL, Xu J, Shi JW, Li JY, Lei PF. · 2026-09-03
open access unreviewed -
3
Systematic enzyme and cofactor engineering for efficient ursolic acid biosynthesis in <i>Yarrowia lipolytica</i>.
Elsharawy H, He Q, Zeng W, Zhou J. · 2026-07-17
open access unreviewed -
4
Ferroptosis: significance to zoonotic diseases and therapeutic prospects.
Tian L, Cheng X, Ni J, Yang R, Ouyang W, Qi T, Liu Q, Wang D, Chen H, Wang X. · 2026-08-25
open access unreviewed -
5
DMAMCL induces ferroptosis in neuroblastoma by targeting HMOX1 in MYCN-amplified subtypes whereas targeting STEAP3 in MYCN-nonamplified subtypes.
Ma Y, Zhang S, Zhang D, Hua Z, Li Z. · 2026-07-13
open access unreviewed -
6
Engineering a heme-dependent tryptophan hydroxylase pathway in <i>E. coli</i> for enhanced melatonin production.
Zhang L, Yin G, Pan S, Zheng X, Zhou S, Du G, Li J, Chen J, Xu R, Kang Z. · 2026-04-11
cited 1× open access unreviewed -
7
Molecular mechanism of Yishen Qingzhuo oral liquid in treating chronic renal failure <i>via</i> the Nrf2/HO-1-mediated ferroptosis pathway.
Zhao A, Chen B, Lin C, Wang W, Su H, Qiu Y, Zhang W. · 2026-04-14
open access unreviewed -
8
Formate as electron carrier in the gut acetogen <i>Blautia luti</i>: a model for electron transfer in the gut microbiome.
Trischler R, Müller V. · 2026-01-02
cited 3× open access unreviewed -
9
Sirt1 attenuates calcific aortic valve disease by inhibiting ferroptosis and enhancing mitochondrial function via the activation of the Nrf2/HO‑1/FTH1 axis.
Yan F, Shi L, Wang Y, Zhao Y, Wu Y, Xian D, Liang Y, Wang N, Cui H, Zhang M. · 2026-09-25
open access unreviewed -
10
Targeting integrated cell death networks in sepsis‑associated acute kidney injury: Shared regulatory nodes and diet‑related small molecule modulation (Review).
Song L, He A, Jiang W, Shi K, Wang J, Xu L, Yu J, Zheng R. · 2026-09-04
open access unreviewed
External claims. These come from an index outside this database and are not checked against it. Treat them as leads.